ID: ALA2385583

Max Phase: Preclinical

Molecular Formula: C22H20N4O

Molecular Weight: 356.43

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  c1ccc(-c2cnn3cc(-c4ccc(N5CCOCC5)cc4)cnc23)cc1

Standard InChI:  InChI=1S/C22H20N4O/c1-2-4-18(5-3-1)21-15-24-26-16-19(14-23-22(21)26)17-6-8-20(9-7-17)25-10-12-27-13-11-25/h1-9,14-16H,10-13H2

Standard InChI Key:  SJQFEHFHHAGMOM-UHFFFAOYSA-N

Associated Targets(non-human)

Bone morphogenetic protein 4 32 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 356.43Molecular Weight (Monoisotopic): 356.1637AlogP: 3.90#Rotatable Bonds: 3
Polar Surface Area: 42.66Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 1.26CX LogP: 3.84CX LogD: 3.84
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.56Np Likeness Score: -1.59

References

1. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR..  (2013)  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.,  23  (11): [PMID:23639540] [10.1016/j.bmcl.2013.03.113]

Source